Natco Pharma Limited - Asset Resilience Ratio
Natco Pharma Limited (NATCOPHARM) has an Asset Resilience Ratio of 63.89% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read NATCOPHARM total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Natco Pharma Limited's Asset Resilience Ratio has changed over time. See NATCOPHARM net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Natco Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NATCOPHARM market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs26.90 Billion | 25.79% |
| Short-term Investments | Rs39.73 Billion | 38.09% |
| Total Liquid Assets | Rs66.64 Billion | 63.89% |
Asset Resilience Insights
- Very High Liquidity: Natco Pharma Limited maintains exceptional liquid asset reserves at 63.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Natco Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Natco Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 6.43% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 6.40% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for Natco Pharma Limited (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Natco Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 31.76% | Rs27.41 Billion ≈ $296.48 Million |
Rs86.31 Billion ≈ $933.39 Million |
+6.95pp |
| 2024-03-31 | 24.82% | Rs17.14 Billion ≈ $185.36 Million |
Rs69.06 Billion ≈ $746.89 Million |
-0.06pp |
| 2023-03-31 | 24.88% | Rs14.07 Billion ≈ $152.19 Million |
Rs56.57 Billion ≈ $611.83 Million |
+12.18pp |
| 2022-03-31 | 12.70% | Rs6.49 Billion ≈ $70.17 Million |
Rs51.09 Billion ≈ $552.53 Million |
-3.83pp |
| 2021-03-31 | 16.53% | Rs7.92 Billion ≈ $85.64 Million |
Rs47.92 Billion ≈ $518.23 Million |
-2.71pp |
| 2020-03-31 | 19.24% | Rs8.83 Billion ≈ $95.46 Million |
Rs45.88 Billion ≈ $496.15 Million |
-4.68pp |
| 2019-03-31 | 23.92% | Rs10.29 Billion ≈ $111.31 Million |
Rs43.03 Billion ≈ $465.36 Million |
+1.72pp |
| 2018-03-31 | 22.20% | Rs8.25 Billion ≈ $89.18 Million |
Rs37.15 Billion ≈ $401.77 Million |
+17.29pp |
| 2017-03-31 | 4.91% | Rs1.14 Billion ≈ $12.30 Million |
Rs23.18 Billion ≈ $250.64 Million |
+3.76pp |
| 2016-03-31 | 1.15% | Rs209.64 Million ≈ $2.27 Million |
Rs18.24 Billion ≈ $197.24 Million |
+1.14pp |
| 2015-03-31 | 0.01% | Rs1.18 Million ≈ $12.79K |
Rs13.84 Billion ≈ $149.68 Million |
-0.02pp |
| 2014-03-31 | 0.03% | Rs3.18 Million ≈ $34.39K |
Rs11.96 Billion ≈ $129.31 Million |
-0.05pp |
| 2013-03-31 | 0.08% | Rs8.12 Million ≈ $87.83K |
Rs10.80 Billion ≈ $116.84 Million |
-0.01pp |
| 2012-03-31 | 0.08% | Rs7.37 Million ≈ $79.76K |
Rs9.03 Billion ≈ $97.63 Million |
-9.70pp |
| 2011-03-31 | 9.78% | Rs691.96 Million ≈ $7.48 Million |
Rs7.07 Billion ≈ $76.49 Million |
+1.43pp |
| 2010-03-31 | 8.36% | Rs460.41 Million ≈ $4.98 Million |
Rs5.51 Billion ≈ $59.58 Million |
-8.29pp |
| 2009-03-31 | 16.65% | Rs859.93 Million ≈ $9.30 Million |
Rs5.17 Billion ≈ $55.86 Million |
+2.77pp |
| 2008-03-31 | 13.88% | Rs581.93 Million ≈ $6.29 Million |
Rs4.19 Billion ≈ $45.36 Million |
-2.82pp |
| 2007-03-31 | 16.69% | Rs583.87 Million ≈ $6.31 Million |
Rs3.50 Billion ≈ $37.83 Million |
+2.74pp |
| 2006-03-31 | 13.95% | Rs429.69 Million ≈ $4.65 Million |
Rs3.08 Billion ≈ $33.30 Million |
-1.36pp |
| 2005-03-31 | 15.31% | Rs439.99 Million ≈ $4.76 Million |
Rs2.87 Billion ≈ $31.08 Million |
-- |
About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; a… Read more